Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8686307 | Neurobiology of Disease | 2018 | 64 Pages |
Abstract
In conclusion, we have revealed a novel neuroprotective activity of MPS that is >100-fold more potent than ethosuximide. This increased potency will facilitate future biochemical studies to identify the direct molecular target(s) of both compounds, as we have shown here that they share a common downstream DAF-16-dependent mechanism of action. Furthermore, MPS is the active metabolite of another approved antiepileptic drug, methsuximide. Therefore, methsuximide may have repurposing potential for treatment of TDP-43 proteinopathies and possibly other human neurodegenerative diseases.
Keywords
PBSTDP-43FTLDDRSPTZBSAMPObovine serum albuminEthosuximideamyotrophic lateral sclerosisMulti-objective optimisationAlzheimer's diseaseALSParkinson's diseaseNeurodegenerationCNSfrontotemporal lobar degenerationcentral nervous systemPhosphate buffered salineMooMPswildtypepolyethylene glycolPEGPentylenetetrazoleCaenorhabditis elegans
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Shi Quan Wong, Matthew G. Pontifex, Marie M. Phelan, Chandra Pidathala, Brian C. Kraemer, Jeff W. Barclay, Neil G. Berry, Paul M. O'Neill, Robert D. Burgoyne, Alan Morgan,